Analysis of the Outcomes of 73 Patients with Exogenous Positive Insulin Anti-Body

References

• Home P, Derwahl KM, Ziemen M, et al. Anti-insulin antibodies and adverse events with biosimilar insulin lispro compared with humalog insulin lispro in people with diabetes. Diabetes Technol Ther. 2018;20:160–170. doi:10.1089/dia.2017.0373
   PubMed Web of Science ®Google Scholar
• Lahtela JT, Knip M, Paul R, Antonen J, Salmi J. Severe antibody-mediated human insulin resistance successful treatment with the insulin analog lispro. Diabetes Care. 1997;20:71–73. doi:10.2337/diacare.20.1.71
   PubMed Web of Science ®Google Scholar
• Timon W, Van Haeften M. Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care. 1989;12:641–648. doi:10.2337/diacare.12.9.641
   Web of Science ®Google Scholar
• Brange J, Ribel U, Hansen JF, et al. Monomeric insulins obtained by protein engineering and their medical implications. Nature. 1988;333:679–682. doi:10.1038/333679a0
   PubMed Web of Science ®Google Scholar
• Cheng M, Yang X, Zhu X, Yao L. Preliminary study on determination of serum insulin antibody in diabetic patients. Chin J Endocrinol Metabol. 1994;10:47–48.
   Google Scholar
• Yao D, Chu J, Cheng S. Clinical analysis 64 cases of T2DM with positive insulin autoantibody induced by exogenous insulin in primary hospital. Mod Pract Med. 2019;31:360–362.
   Google Scholar
• Li F, Wu Z, Chi Q, Qiao X, Wang S. Immunogenicity of recombinant human insulin in treatment of type 2 diabetes mellitus. Chin J Clin. 2013;7:9081–9084.
   Google Scholar
• Yao D, Zhu ZQ, Chen ZY, et al. Insulin antibody as a biomarker to monitor the development of type 2 diabetes in county hospitals in China. Int J Diabetes Dev Ctries. 2022. doi:10.1007/s13410-022-01110-2
   Web of Science ®Google Scholar
• Matsuyoshi A, Shimoda S, Tsuruzoe K, et al. A case of slowly progressive type 1 diabetes with unstable glycemic control caused by unusual insulin antibody and successfully treated with steroid therapy. Diabetes Res Clin Pract. 2006;72(3):238–243. doi:10.1016/j.diabres.2005.10.018
   Web of Science ®Google Scholar
• Uchigata Y, Kuwata S, Tokunaga K, et al. Strong association of insulin autoimmune syndrome with HLA-DR4. Lancet. 1992;339:393–394. doi:10.1016/0140-6736(92)90080-M
   PubMed Web of Science ®Google Scholar
• Xia LM, Zhang AP, Zheng Q, et al. Quercetin-3-O-β-D-glucuronide inhibits mitochondria pathway-mediated platelet apoptosis via the phosphatidylinositol-3-kinase/ AKT pathway in immunological bone marrow failure. World J Tradit Chin Med. 2022;8:115–122. doi:10.4103/wjtcm.wjtcm_44_21
   Google Scholar
• Hu X, Chen F. Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients. Endocr Connect. 2018;7:R47–R55. doi:10.1530/EC-17-0309
   Web of Science ®Google Scholar
• Tamura Y, Kimbara Y, Funatsuki S, et al. A case of insulin antibody-induced glucose instability in an elderly woman with type 2 diabetes on hemodialysis, successfully ameliorated with liraglutide. Diabetol Int. 2013;4(1):71–75. doi:10.1007/s13340-012-0100-0
   Google Scholar
• Airaghi L, Lorini M, Tedeschi A. The insulin analog aspart a safe alternative in insulin allergy. Diabetes Care. 2001;24:2000. doi:10.2337/diacare.24.11.2000
   PubMed Web of Science ®Google Scholar
• Yasuda H, Nagata M, Moriyama H, et al. Human insulin analog insulin aspart does not cause insulin allergy. Diabetes Care. 2001;24:2009. doi:10.2337/diacare.24.11.2008
   Web of Science ®Google Scholar
• Moriyama H, Nagata M, Fujihira K, et al. Treatment with human analog insulin glargine resolves a generalized allergy to human insulin in type 1 diabetes. Diabetes Care. 2001;24:411–412. doi:10.2337/diacare.24.2.411
   PubMed Web of Science ®Google Scholar
• Yoshida M, Asai M, Miyata M, Ogawa K, Maeda H, Oiso Y. Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy. Diabetes Res Clin Pract. 2012;96:e55–56. doi:10.1016/j.diabres.2011.12.024
   Web of Science ®Google Scholar
• Ionescu-Tirgoviste C, Mincu I, Simionescu L, et al. Disappearance rate of insulin antibodies after discontinuing insulin treatment in 42 type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1984;27:592–595. doi:10.1007/BF00276974
   Web of Science ®Google Scholar
• Koyama R, Nakanishi K, Kato M, Yamashita S, Kuwahara H, Katori H. Hypoglycemia and hyperglycemia due to insulin antibodies against therapeutic human insulin. Am J Med Sci. 2005;329:259–264. doi:10.1097/00000441-200505000-00007
   PubMed Web of Science ®Google Scholar
• Haeften TWV, Krom BA, Gerich JE. Prolonged fasting hypoglycemia due to insulin antibodies in patient with non-insulin-dependent diabetes mellitus effect of insulin withdrawal on insulin-antibody-binding kinetics. Diabetes Care. 1987;10:160–163. doi:10.2337/diacare.10.2.160
   Web of Science ®Google Scholar
• Rajan S, Shankar K, Beg M, et al. Chronic hyperinsulinemia reduces insulin sensitivity and metabolic functions of brown adipocyte. J Endocrinol. 2016;230:275–290. doi:10.1530/JOE-16-0099
   Web of Science ®Google Scholar
• Asai M, Kodera T, Ishizeki K, et al. Insulin lispro reduces insulin antibodies in a patient with type 2 diabetes with immunological insulin resistance. Diabetes Res Clin Pract. 2003;61:89–92. doi:10.1016/S0168-8227(03)00105-0
   Web of Science ®Google Scholar
• Zhou F, Tian H. Clinical significance of exogenous insulin induced insulin antibody production in diabetic patients. J Pract Hosp Clin. 2014;11:18–21.
   Google Scholar
• Zhu L, Zhu Y, Sun K, et al. Diagnosis and treatment of insulin autoimmune syndrome induced by exogenous insulin: a case report and literature review. Chin J Diabetes. 2017;25:743–747.
   Google Scholar
• Sauerborn M, Brinks V, Jiskoot W, Schellekens H. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci. 2010;31:53–59. doi:10.1016/j.tips.2009.11.001
   PubMed Web of Science ®Google Scholar
• Asai M, Yoshida M, Miura Y. Immunologic tolerance to intravenously injected insulin. N Engl J Med. 2006;354:307–309. doi:10.1056/NEJMc052463
   Web of Science ®Google Scholar
• Galloway JA, Root MA, Bergstrom R, et al. Clinical pharmacologic studies with human insulin (recombinant DNA). Diabetes Care. 1982;5:13–22. doi:10.2337/diacare.5.2.S13
   PubMed Web of Science ®Google Scholar
• Hirai H, Ogata E, Kikuchi N, et al. The effects of liraglutide on both hypereosinophilic insulin allergy and the characteristics of anti-insulin antibodies in type 2 diabetes mellitus: a case report. J Med Case Rep. 2016;10:202. doi:10.1186/s13256-016-0994-4
   PubMedGoogle Scholar
• Ouyang X, Bian R, Gu L, et al. Analysis of insulin antibody production in patients with type 2 diabetes mellitus. Selected papers of 2015 geriatric Annual Conference 43-44; 2015.
   Google Scholar